Gemphire Therapeutics, a clinical-stage biopharmaceutical company and NeuroBo Pharmaceuticals, a privately-held clinical-stage biotechnology company, have entered into a definitive agreement whereby NeuroBo will merge with a wholly-owned subsidiary of Gemphire in an all-stock transaction.
-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash.
Boehringer Ingelheim has signed a new collaboration and licence agreement with Bridge Biotherapeutics to develop autotaxin inhibitor BBT-877 to treat patients with fibrosing interstitial lung diseases.
Astellas Pharma has signed a licensing deal worth up to $625m (£500.66m) with Frequency Therapeutics to develop and commercialise FX-322, the latter’s regenerative therapeutic candidate for the treatment of sensorineural hearing loss.
AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
Recordati announces the signing of an agreement with Novartis for the acquisition of worldwide rights to Signifor and Signifor LAR for the treatment of Cushing’s disease and acromegaly in adult patients for whom surgery is not an option or for whom surgery has failed.
Boehringer Ingelheim has acquired Swiss biotechnology firm AMAL Therapeutics in a deal valued at around €325m (£291.9m).
Biopharmaceutical firm Gilead Sciences has entered into a 10-year global research and development collaboration with Galapagos.
Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease.
Jazz Pharmaceuticals has signed a definitive agreement for the acquisition of Redx Pharma's pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.